hepat
c
viru
hcv
infect
major
public
health
problem
sinc
case
caus
chronic
hepat
hepat
cirrhosi
hepatocellular
carcinoma
current
treatment
chronic
hepat
c
base
combin
pegyl
interferonalpha
ribavirin
howev
approxim
treat
patient
infect
genotyp
respond
show
partial
transient
respons
therapi
caus
signific
side
effect
japan
glycyrrhizin
gl
prepar
stronger
neominophagen
c
snmc
use
year
treatment
chronic
hepat
patient
respond
ifn
therapi
gl
major
compon
licoric
root
extract
compos
glycyrrhetin
acid
gl
shown
possess
sever
benefici
pharmacolog
activ
includ
antiinflammatori
activ
antitumor
activ
antiallerg
activ
antivir
activ
sever
mechan
glinduc
antiinflammatori
effect
report
inhibit
thrombininduc
platelet
aggreg
inhibit
prostaglandin
product
inhibit
phospholipas
mani
antivir
effect
gl
report
previous
exampl
herp
simplex
type
varicellazost
viru
vzv
hepat
hav
b
viru
hbv
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
sar
coronaviru
viru
ebv
human
cytomegaloviru
influenza
viru
gl
consid
potenti
treatment
patient
chronic
hepat
c
long
term
administr
gl
patient
effect
suppress
serum
alanin
aminotransferas
alt
level
histolog
chang
howev
direct
antivir
effect
gl
hcv
never
report
studi
evalu
antihcv
effect
gl
demonstr
gl
target
releas
step
infecti
hcv
particl
infect
cell
found
suppress
viru
releas
gl
may
deriv
inhibitori
effect
group
find
suggest
possibl
novel
role
gl
treatment
patient
chronic
hepat
c
human
hepatoma
cell
line
deriv
cell
line
provid
franci
chisari
scripp
research
institut
la
jolla
ca
maintain
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
cell
harbor
subgenom
replicon
maintain
complet
dmem
supplement
mgml
geneticin
life
technolog
japan
ltd
tokyo
japan
gl
acid
kindli
provid
minophagen
pharmaceut
co
ltd
tokyo
japan
msd
kk
tokyo
japan
respect
oleyloxyethyl
phosphorylcholin
opc
cayman
chemic
compani
ann
arbor
mi
inhibitor
merck
darmstadt
germani
antiactin
santa
cruz
biotechnolog
santa
cruz
ca
antihuman
bd
pharmingen
san
jose
ca
antibodi
purchas
solvent
distil
water
gl
ethanol
opc
dmso
inhibitor
product
cell
cultureproduc
hcv
hcvcc
previous
report
purif
ld
previous
report
concentr
hcv
core
antigen
filter
cultur
medium
cell
lysat
ld
fraction
infect
cell
determin
use
lumipuls
ortho
hcv
antigen
kit
ortho
clinic
diagnost
tokyo
japan
cell
viabil
analyz
use
cell
titerglo
luminesc
cell
viabil
assay
promega
madison
wi
accord
manufactur
protocol
electropor
hcv
rna
lack
vitro
synthesi
hcv
rna
lack
electropor
perform
describ
previous
hcvpp
harbor
glycoprotein
clone
genotyp
th
clone
genotyp
produc
previous
describ
pseudotyp
viru
vsv
g
glycoprotein
vsvpp
also
gener
cell
seed
plate
incub
overnight
infect
hcvpp
presenc
variou
concentr
gl
sever
hour
postinfect
medium
replac
dmem
fb
cell
harvest
hour
later
determin
intracellular
luciferas
activ
luciferas
assay
system
promega
assay
genotyp
subgenom
report
replicon
previous
report
hour
treatment
gl
replicontransfect
cell
harvest
either
measur
luciferas
activ
promega
hcv
rna
titer
describ
previous
replic
effici
hcv
prepar
calcul
percentag
luciferas
activ
hcv
rna
titer
compar
cell
subject
control
treatment
determin
extracellular
hcv
infect
cell
inocul
cell
cultur
supernat
medium
contain
hcvcc
hour
incub
medium
replac
dmem
contain
fb
cell
cultur
addit
hour
infecti
hcv
titer
cultur
medium
determin
quantif
use
lumipuls
ortho
hcv
antigen
kit
immunostain
hcv
core
antigen
use
immunoassay
also
provid
result
indic
hcv
infect
confirm
good
correl
level
core
antigen
infecti
titer
data
shown
estim
intracellular
infect
cell
cultur
plate
fill
dmem
contain
fb
subject
four
cycl
freez
thaw
use
dri
ice
water
bath
cell
cultur
plate
centrifug
rpm
min
remov
cell
debri
supernat
collect
evalu
infect
sirna
target
scrambl
neg
control
sirna
purchas
sigma
tokyo
japan
cell
plate
transfect
sirna
use
hiperfect
transfect
reagent
qiagen
tokyo
japan
follow
manufactur
instruct
quantif
triglycerid
triglycerid
tg
measur
triglycerid
kit
wako
tokyo
japan
accord
manufactur
instruct
inocul
cell
fix
methanol
immunostain
mous
monoclon
anticor
antibodi
rabbit
polyclon
antibodi
follow
alexa
fluor
antimous
secondari
antibodi
life
technolog
japan
ltd
cell
fix
glutaraldehyd
cacodyl
buffer
ph
min
postfix
phosphat
buffer
ph
hour
cell
dehydr
ethanol
embed
epon
ultrathin
section
doubl
stain
examin
acceler
voltag
kev
immunoem
iem
perform
use
label
strept
avidinbiotin
lab
kit
accord
manufactur
instruct
zyme
laboratori
san
francisco
ca
describ
previous
assay
perform
least
four
independ
experi
data
express
mean
sd
statist
analysi
perform
use
student
test
assess
antihcv
effect
gl
hcvccinfect
cell
treat
variou
concentr
gl
hour
level
hcv
core
antigen
infect
medium
determin
hcv
core
antigen
level
reduc
gl
figur
shown
figur
infect
supernat
follow
gl
treatment
reduc
control
level
respect
calcul
effect
concentr
effect
cell
viabil
treatment
figur
result
suggest
gl
effect
inhibit
product
infecti
hcv
hcv
propag
hepatocyt
throughout
lifecycl
includ
stage
attach
entri
uncoat
translat
genom
replic
assembl
bud
releas
investig
step
hcv
lifecycl
gl
inhibit
use
hcvpp
system
evalu
attach
entri
hcv
replicon
system
translat
genom
replic
treatment
gl
result
moder
reduct
luciferas
activ
cell
infect
hcvpp
valu
figur
hand
signific
reduct
luciferas
activ
cell
infect
figur
vsvpp
figur
cytotox
effect
gl
observ
data
shown
cell
harbor
subgenom
replicon
treat
variou
concentr
gl
hour
rel
luciferas
activ
gltreat
cell
inhibit
dosedepend
manner
valu
figur
similar
result
obtain
use
subgenom
replicon
data
shown
also
transfect
hcv
rna
lack
monitor
effect
gl
hcv
replic
avoid
reinfect
cell
signific
reduct
hcv
rna
titer
cell
figur
signific
cytotox
seen
follow
treatment
data
shown
investig
effect
gl
entri
hcv
particl
treat
increas
concentr
gl
viral
sampl
use
inocul
cell
cultur
glcontain
medium
sever
hour
postinfect
medium
replac
dmem
without
gl
level
hcv
core
antigen
medium
determin
h
postinfect
pi
signific
reduct
hcv
product
figur
result
indic
gl
inhibit
hcv
entri
replic
significantli
assess
whether
gl
treatment
affect
step
viral
lifecycl
analyz
infecti
hcv
particl
assembl
releas
follow
gl
treatment
supernat
crude
cell
lysat
hcvccinfect
cell
treat
gl
use
inocul
cell
determin
extra
intracellular
specif
infect
respect
specif
infect
determin
ratio
infecti
viru
titer
hcv
core
antigen
level
describ
previous
shown
figur
extracellular
specif
infect
titer
inhibit
gl
concentr
hand
intracellular
specif
infect
titer
increas
control
concentr
gl
figur
signific
cytotox
follow
treatment
data
shown
previous
report
viru
assembl
take
place
around
lipid
droplet
ld
immunofluoresc
stain
examin
subcellular
coloc
hcv
core
figur
figur
ld
hcvccinfect
cell
without
gl
treatment
uninfect
cell
shown
figur
observ
hcv
protein
coloc
ld
figur
intens
profil
along
line
segment
shown
bottom
imag
demonstr
core
protein
tightli
coloc
ld
hcvccinfect
cell
treat
gl
compar
untreat
cell
figur
lower
panel
quantifi
size
ld
hcvinfect
cell
figur
uninfect
cell
figur
gltreatment
found
gl
affect
size
ld
uninfect
cell
figur
right
panel
hand
size
ld
increas
hcvinfect
cell
gltreatment
figur
left
panel
hcvccinfect
cell
figur
uninfect
cell
figur
treat
gl
prepar
em
analysi
cytoplasm
hcvinfect
cell
observ
increas
number
ld
close
proxim
endoplasm
reticulum
er
electrondens
signal
er
attach
ld
figur
upper
panel
thought
act
platform
assembl
viral
compon
interestingli
cytoplasm
hcvinfect
cell
treatment
gl
accumul
electrondens
particl
observ
er
attach
ld
figur
lower
panel
iem
experi
show
anticor
antibodi
stain
membran
around
ld
figur
lower
panel
cell
close
associ
ld
er
rare
observ
figur
confirm
accumul
core
antigen
around
ld
purifi
ld
quantifi
hcv
core
antigen
tg
ld
fraction
follow
immunoblot
antiactin
antibodi
figur
analysi
level
hcv
core
antigen
tg
ld
fraction
total
cell
lysat
show
amount
gltreat
cell
increas
compar
control
respect
figur
taken
togeth
result
suggest
gl
inhibit
releas
assembl
bud
infecti
hcv
particl
cell
character
infect
hcv
particl
releas
hcvccinfect
cell
treat
gl
supernat
cell
cultur
treat
treat
gl
subject
continu
wv
sucros
densiti
gradient
centrifug
infect
titer
fraction
measur
reduct
infect
gltreatment
observ
fraction
figur
result
suggest
gl
may
decreas
amount
hcv
infecti
particl
supernat
gl
known
inhibitori
effect
classifi
sever
group
biolog
function
unknown
group
target
gl
analyz
effect
gl
major
group
famili
confirm
effect
gl
express
cell
transfect
express
plasmid
treat
gl
opc
specif
inhibitor
treatment
gl
effect
decreas
cellular
level
figur
verifi
whether
role
viral
entri
replic
test
effect
inhibitor
hcvpp
infect
replicon
system
respect
opc
signific
effect
viru
entri
replic
figur
hand
inhibitor
specif
inhibitor
inhibit
hcvpp
entri
figur
subgenom
replicon
replic
figur
signific
cytotox
seen
treatment
data
shown
evalu
effect
inhibitor
hcvcc
infect
infect
cell
treat
inhibitor
extra
intracellular
specif
infect
measur
figur
opc
slightli
decreas
specif
infect
viru
supernat
significantli
increas
specif
infect
viru
cell
lysat
hand
inhibitor
significantli
decreas
specif
infect
viru
supernat
cell
lysat
confirm
import
hcv
releas
silenc
specif
sirna
monitor
effect
hcv
releas
sirna
decreas
cellular
level
figur
suppress
reduc
core
protein
level
medium
figur
left
panel
increas
specif
infect
cell
figur
right
panel
perform
gl
treatment
without
opc
show
gl
opc
addit
effect
appli
togeth
figur
signific
cytotox
seen
treatment
data
shown
taken
togeth
result
suggest
suppress
viru
releas
gl
may
deriv
inhibitori
effect
result
also
suggest
role
viru
releas
demonstr
target
caus
antihcv
effect
gl
differ
ifn
analyz
antivir
effect
ifn
combin
gl
hcvccinfect
cell
treat
iuml
ifn
combin
variou
concentr
gl
hcv
core
level
cultur
medium
figur
cell
figur
specif
infect
cultur
medium
figur
cell
figur
measur
regardless
ifn
concentr
hcv
core
level
specif
infect
supernat
decreas
respons
gl
treatment
dose
depend
manner
figur
hand
hcv
core
level
specif
infect
cell
increas
figur
suggest
gl
inhibit
hcv
releas
result
indic
combin
therapi
ifn
gl
could
effect
treatment
hcv
ifninduc
abil
gl
also
previous
report
evalu
ifn
stimul
gene
induct
gl
effect
observ
figur
known
associ
variou
intracellular
traffick
event
secret
lowdens
lipoprotein
vldl
hcv
particl
known
secret
use
host
membran
traffick
system
increas
evid
vldl
particip
hcv
assembl
releas
therefor
analyz
level
albumin
abundantli
secret
protein
hepatocyt
apolipoprotein
e
apo
compon
lipoprotein
cultur
supernat
cell
found
influenc
gl
treatment
figur
recent
ashfaq
et
al
found
inhibitori
effect
gl
hcv
product
patient
serum
infect
cell
cell
cultur
system
produc
hcv
effici
thu
permit
analysi
complet
viral
life
cycl
studi
observ
distinct
suppress
hcv
releas
gl
use
hcvcc
system
figur
antivir
effect
gl
earli
step
viral
lifecycl
report
previous
exampl
inhibit
endocytosi
influenza
viru
iav
direct
fusion
penetr
plasma
membran
hav
ebv
viru
entri
sar
infect
pseudorabi
viru
gl
effect
inhibit
replic
vzv
ebv
hiv
first
report
gl
suppress
viru
releas
howev
detail
mechan
remain
elus
also
report
gl
membran
stabil
effect
reduct
membran
fluiditi
hcv
use
cellular
membran
structur
lifecycl
thu
conceiv
membran
alter
may
play
neg
role
hcv
lifecycl
found
core
protein
accumul
ld
gltreat
cell
figur
invers
correl
effici
viru
product
core
protein
accumul
ld
also
observ
coloc
hcv
protein
ld
low
case
chimera
support
higher
infect
titer
compar
studi
demonstr
gl
affect
size
ld
uninfect
cell
figur
right
panel
hand
size
ld
increas
hcvinfect
cell
gltreatment
figur
left
panel
probabl
accumulatedhcv
enhanc
format
ld
demonstr
import
hcv
releas
inhibitor
sirna
figur
overexpress
effect
hcv
releas
data
shown
probabl
enough
exist
cell
result
gener
observ
host
factor
involv
hcv
lifecycl
exampl
overexpress
human
homologu
vesicleassoci
membran
proteinassoci
protein
critic
role
format
hcv
replic
complex
increas
hcv
replic
famili
protein
known
lipidsign
molecul
induc
inflamm
basi
nucleotid
sequenc
superfamili
enzym
consist
group
compris
main
type
cytosol
calciumindepend
platelet
activ
factor
acetyl
hydrolaseoxid
lipid
lipoprotein
associ
secretori
includ
studi
show
gl
inhibitor
sirna
inhibit
hcv
releas
gl
opc
addit
effect
appli
togeth
suggest
suppress
hcv
releas
gl
may
deriv
inhibitori
effect
role
hcv
lifecycl
report
studi
also
demonstr
inhibitor
decreas
entri
replic
assembl
infecti
hcv
particl
cell
figur
role
hcv
lifecycl
report
known
affect
secret
vldl
therefor
may
contribut
hcv
assembl
case
menzel
et
al
show
inhibit
produc
aberr
hcv
particl
observ
suggest
role
sever
step
hcv
lifecycl
studi
show
gl
treatment
intracellular
infect
figur
report
maximum
peripher
concentr
gl
normal
patient
placebocontrol
phase
iii
trial
reveal
signific
effect
viral
titer
vivo
accumul
hcv
gl
treat
cell
may
caus
lysi
apoptosi
cell
lead
releas
infecti
particl
circul
may
major
limit
use
gl
monotherapi
hcv
infect
patient
hand
combin
treatment
gl
augment
ifninduc
reduct
hcv
core
antigen
level
figur
although
number
natur
compound
antihcv
activ
identifi
recent
year
silymarin
egcg
ladanein
naringenin
quercetin
luteolin
honokiol
caruilignan
c
thing
mani
aspect
concern
mechan
action
remain
unknown
studi
gl
identifi
novel
antihcv
agent
target
releas
step
infecti
hcv
particl
found
suppress
viral
releas
gl
may
due
inhibitori
effect
observ
provid
basi
develop
improv
ifnbas
combin
therapi
chronic
hepat
c
